Article thumbnail

Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma

By Eugeniusz Samojlik, Johannes D. Veldhuis, Samuel A. Wells and Richard J. Santen


of aminoglutethimide (AG) on androgen and estrogen levels estrone ([EJ], estradiol [E2], plasma dehydro-epiandrosterone-sulfate [DHEA-S], testosterone [T], dihydrotestosterone [DHT], A4-androstenedione [A4-A]), follicle-stimulating hormone (FSH), luteinizing hor-mone (LH), and prolactin in postmenopausal patients with breast cancer randomly allocated to either AG treatment or bilateral surgical adrenalectomy as a control group. In response to either treatment, the plasma levels of El fell 62-75 % (P < 0.001) and urine El 85.7-88.7 % (P <0.001) in all study days over a 12-wk period. Similarly, the concentrations of E2 in plasma and urine fell 40-72 % without statistically significant differences between the two treatment modalities. The relatively weak androgen, DHEA-S, was re-duced by 92 % (877.3±184.6 to 71.8±14.5 ng/ml) at 12 wk in women treated with AG, but suppressed nearly 99 % (1,151+262 to 5.8±3.3 ng/ml) in adrenalectomized women. At all time points after treatment, the DHEA-S levels were significantly higher in patients receiving AG. Plasma concentrations of the potent androgens, T and DHT, were also relatively preserved during AG treatment. T levels were never significantly reduced by AG, and DHT concentrations were decreased only at the 4th wk to a maximum of 20%. A4-A levels fell 56 % in response to this drug only on the 12th wk o

Year: 1980
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dm5migu4zj3pb.cloudfron... (external link)
  • http://dm5migu4zj3pb.cloudfron... (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.